Growth-hormone release
Its ability to trigger growth-hormone release is the clearest research-supported reason for interest in ipamorelin.
Explore the research →GH SECRETAGOGUE RESEARCH
Ipamorelin
Ipamorelin stimulates growth-hormone release and is commonly discussed in relation to recovery, sleep and body composition.
Growth hormoneRecoveryBody composition
Early human and preclinical evidenceIpamorelin has human pharmacology data, but robust evidence for commonly promoted recovery, muscle or anti-ageing outcomes remains limited.
FOLLOW THE FULL PICTUREFrom interest to evidence, quality and the numbers.
Why are people interested in Ipamorelin?
Ipamorelin attracts interest because it encourages the body to release more of its own growth hormone. Growth hormone is involved in recovery, tissue repair and body composition, which naturally puts ipamorelin into conversations around sleep, muscle, recovery and staying lean. Those are the potential benefits that have driven much of the interest around it.
Recovery
Recovery and tissue support are among the most common goals associated with ipamorelin in community use.
Explore the research →Muscle & body composition
Interest often centres on gaining or preserving lean mass while supporting a leaner body composition.
Explore the research →A more selective approach
Part of ipamorelin's appeal is that it was designed to stimulate growth hormone more selectively than some earlier compounds in the same family.
Explore the research →THE SCIENCE BIT
Using the ghrelin receptor to signal GH release.
Ipamorelin activates the growth-hormone secretagogue receptor, also known as the ghrelin receptor or GHS-R1a. This is a different starting point from the GHRH receptor used by sermorelin and CJC-type peptides.
The resulting signal can stimulate growth-hormone release. Its reputation for selectivity comes largely from early pharmacology; that does not make every long-term wellness claim established.
See the studies & trials →- GHS-R1a
- The ghrelin receptor
- Pituitary
- GH release
- Selectivity
- Studied in early pharmacology
How this connects to the research
Early human pharmacology is stronger than the evidence for wider wellness outcomes.
Read a primary source ↗FROM MOLECULE TO TISSUE
Where Ipamorelin connects with the body
These are the tissues and biological systems behind the interest in Ipamorelin.
- Pituitary
- Hormone secretion.
- Hypothalamus
- GH-regulating networks.
- Peripheral tissues
- Downstream hormone effects.
The research behind the interest
Growth-hormone release
Its ability to trigger growth-hormone release is the clearest research-supported reason for interest in ipamorelin.
Human studies confirm that ipamorelin can stimulate growth-hormone release through the ghrelin receptor system.
Early human evidenceExplore the studies →Recovery
Recovery and tissue support are among the most common goals associated with ipamorelin in community use.
The idea is largely based on what growth hormone does in the body; strong trials showing better recovery specifically from ipamorelin are still lacking.
Mechanistic rationaleExplore the studies →Muscle & body composition
Interest often centres on gaining or preserving lean mass while supporting a leaner body composition.
Direct evidence showing clinically meaningful changes in muscle or body fat from ipamorelin remains limited.
Limited evidenceExplore the studies →A more selective approach
Part of ipamorelin's appeal is that it was designed to stimulate growth hormone more selectively than some earlier compounds in the same family.
Researchers have explored whether that selectivity changes its hormonal side-effect profile, although the practical clinical significance is not yet clear.
Pharmacology evidenceExplore the studies →Studies & trials
Studies & trials
Original publication · PubMed · trial registry where availablePharmacokinetic-pharmacodynamic modeling of ipamorelin in human volunteers ↗
Healthy male volunteers; eight subjects at each of five dose levels
Intravenous infusionSingle 15-minute infusionAcute pharmacokinetic/pharmacodynamic observation
Ipamorelin showed dose-proportional pharmacokinetics across the five infusion rates studied.
Growth hormone rose in a single pulse, peaking at about 0.67 hours, while the terminal half-life of ipamorelin was approximately 2 hours.
Evidence snapshot
Evidence snapshot
Separate dimensions, not one overall score◎
Human evidenceLimited
2/5 evidence depth
✓
Clinical efficacyLimited
2/5 evidence depth
This score reflects completed human outcome evidence. A registered or recruiting trial does not count until results are reported.
◇
Safety evidenceLimited
2/5 evidence depth
⌁
Preclinical evidenceDeveloping
3/5 evidence depth
HOW TO READ THESE SCORESDeveloping preclinical evidence · limited human evidence
These are editorial evidence-depth ratings on a 1–5 scale, not a statistical result or a single scientific formula. They summarise how much relevant evidence is present in each separate category and how mature that evidence is.
Human evidenceHow much direct research in people is available and how developed it is.
Clinical efficacyWhether human studies demonstrate meaningful outcomes for the claims being discussed.
Safety evidenceHow much human safety, tolerability and longer-term follow-up information is available.
Preclinical evidenceThe depth of laboratory and animal research supporting biological plausibility.
HOW THE EVIDENCE IS ORGANISED
Ipamorelin research profile
Research themes are shown separately from the strength of the human evidence so biological interest is not confused with proven clinical benefit.
RESEARCH AREA 01Growth hormone
RESEARCH AREA 02Recovery
RESEARCH AREA 03Body composition
RESEARCH AREA 04Ghrelin signalling
Mechanistic and preclinical findings are context for further research; they are not treated as equivalent to demonstrated human outcomes.
From promising signals to human evidencePreclinical research can reveal promising biological signals. Human studies show how far those signals have translated into real-world outcomes.
What people are exploring
COMMUNITY · USE CASES & EXPERIENCE
What people want to change with Ipamorelin
Ipamorelin is popular because it produces a measurable growth-hormone signal and is described as more selective than earlier secretagogues. Community goals are broader—sleep, recovery and body composition—than the outcomes tested in people.
Explore the everyday goalsConceptual scientific illustration
THE PRACTICAL ATTRACTION
The goals behind the interest
What the desired change means in daily life, and what makes an experience useful to understand.
Feeling recovered enough for the next session
Training interest centres on tolerating repeated sessions with less perceived soreness or fatigue. The selective growth-hormone-release story makes it attractive, but the desired outcome is function rather than a laboratory hormone rise.
- What makes a report informative
- Repeat-session performance and soreness at the same workload.
- What can muddy the picture
- CJC-1295, training changes and nutrition frequently complicate attribution.
Better sleep and morning readiness
People interested in sleep want fewer unrefreshing nights and better daytime readiness. A report is more useful when it distinguishes sleep onset, staying asleep and how the following day feels.
- What makes a report informative
- Sleep continuity and morning or daytime function.
- What can muddy the picture
- Bedtime routines and other sleep-related products can have similar effects.
A leaner look while maintaining muscle
Body-composition interest includes maintaining training capacity during fat loss or building a more muscular appearance. A change in GH signalling alone does not establish either result.
- What makes a report informative
- Strength and waist trends alongside body weight.
- What can muddy the picture
- Fluid changes, diet and resistance training can explain visible changes.
FROM PUBLIC DISCUSSIONS
Experiences worth looking at
Selected first-hand accounts illustrate the goals and the variation in experience. They are examples, not a representative sample or proof of an effect.
Sleep that became worse rather than better
Participants describe disrupted sleep, including combination use. This is a counterexample to the idea that a sleep benefit is guaranteed.
Read the discussionPositive sleep impressions with a combination
A participant describes better sleep and some morning grogginess with CJC-1295/ipamorelin. The account cannot separate the two compounds.
Read the discussionPUT THE EXPERIENCE IN CONTEXT
How the goals compare with the research
Open an area to distinguish human findings from laboratory explanations.
A cleaner GH pulse
Human findings & limits
A small healthy-volunteer study confirmed a single GH pulse after intravenous ipamorelin and mapped its short-term pharmacology.
Laboratory & animal context
Ghrelin-receptor selectivity is the basis for the ‘cleaner’ description, but selectivity does not remove all downstream risks.
What this means: GH release is demonstrated; a superior everyday side-effect profile is not firmly established.
Better sleep and recovery
Human findings & limits
Controlled human trials have not established sleep, injury recovery or training adaptation as reliable outcomes.
Laboratory & animal context
Growth-hormone physiology provides an indirect rationale rather than direct proof.
What this means: A common experience claim that still needs outcome-focused human research.
Lean mass and fat-loss support
Human findings & limits
The available human pharmacology work did not test a community-style body-composition programme.
Laboratory & animal context
A GH pulse alone cannot predict meaningful changes in muscle or body fat.
What this means: Not established as a body-composition treatment.
Research sources and further reading
Dose & duration
DOSE & DURATION
Research protocols · community patterns · calculator toolsSee the numbers in their proper context
See the amount, how often it was used and how long each study ran. Published human research and community descriptions each carry their own source label, so you can see where the numbers came from.
Source matters. The figures below show authorised, human-research or community-described protocols in their original context — not a personalised recommendation.
Published human work is primarily pharmacokinetic/pharmacodynamic research rather than validated body-composition, recovery or anti-ageing treatment protocols.
PUBLISHED HUMAN RESEARCH
View source ↗Healthy-volunteer PK/PD dose-escalation study ↗
Healthy male volunteers
WHAT THIS TRIAL EXAMPLE SHOWS
This was a published human study. It involved Healthy male volunteers. Route: Given into a vein (IV). The study lasted acute study. The figures below describe the research design, not a personal schedule.
| First amount studied | 4.21 nmol/kg given slowly over time |
|---|---|
| Later or target amount | 140.45 nmol/kg given slowly over time |
| How often? | Single 15-minute infusion |
| How was it given? | Given into a vein (IV) |
| How long? | Acute study |
See the exact study wording +
Start / initial: 4.21 nmol/kg infusion
End / target: 140.45 nmol/kg infusion
Frequency: Single 15-minute infusion
Route: Intravenous
Study duration: Acute study
Source: PMID 10496658 ↗
Experimental infusion protocol; not a clinical dosing recommendation.
COMMUNITY DISCUSSION
Anecdotal subcutaneous pattern · human study used IV infusionWhat people commonly discuss
STARTING APPROACHES
Community routines often begin around 100 mcg once daily, commonly near bedtime. Human research does not validate this subcutaneous starting amount.
DURATION / CYCLES
Daily or divided 100–300 mcg-per-use patterns over roughly eight-to-twelve weeks are widely discussed, sometimes alongside a GHRH analogue.
MAINTENANCE DISCUSSION
A pause after a short cycle is commonly described. No evidence-based maintenance dose, tolerance strategy or break interval exists.
Community patterns are anecdotal and unvalidated unless a linked human study independently supports the same approach.
COMMUNITY-REPORTED PRACTICEInjection patterns people commonly discussPopular uses · route · site discussion · timing · durationCommon anecdotal consensus
RecoverySleep-related interestBody-composition goalsGrowth-hormone-related interest
ROUTE PEOPLE DISCUSS
Subcutaneous injection is the route most commonly discussed by users.
INJECTION-SITE DISCUSSION
Routine subcutaneous sites such as the abdomen are commonly mentioned. There is no established evidence that injecting near a target muscle or injury improves the effect.
TIMING PEOPLE DISCUSS
Bedtime, evening, or fasted use is frequently discussed because of the compound's growth-hormone secretagogue activity.
DURATION / CYCLE DISCUSSION
Multi-week cycles are commonly discussed, often in combination with CJC-1295, but these are anecdotal protocols rather than validated treatment courses.
What the evidence supports
Human studies demonstrate growth-hormone release, but community protocols for recovery, sleep or body composition are not established clinical uses.
Community reports describe what people say they do; they are not instructions, validated protocols, or evidence that a particular injection site or timing improves outcomes.CALCULATOR TOOLS
Work with the numbers
Convert amounts, concentration, liquid volume and vial requirements. These tools do the arithmetic; they do not select a dose.
NEED HELP READING THE NUMBERS?Source labels, routes and dose termsOpen guide +
HOW WE LABEL NUMBERSKnow where a dose came from before you compare it.
Authorised labelHuman trialCommunity-describedBEFORE THE NUMBERS: CHECK THE PRODUCT
Understand peptide testing →A dose only means something if the vial contains what the label says.
Purity, identity, quantity, sterility and endotoxin testing answer different questions. Learn how to read a COA and why a high purity percentage is not the same as confirming the amount in the vial.
READ THIS PAGE IN THREE STEPS
Understand the study before the number
A dose only makes sense alongside the population, route, frequency and duration. Start with where the number came from, then look at how it was delivered and how long the study actually ran.
1Source
Was it an authorised label, a human trial or a community-described pattern?
2Route & frequency
How was it given, and how often? The same number by a different route may not mean the same exposure.
3Duration
Was this one dose, a short trial or long-term treatment? A study window is not automatically a recommended cycle.
ROUTES EXPLAINED
Plain-English guideWhat do the injection types mean?
Route means how a compound was delivered. It affects absorption and can completely change how a study should be interpreted.
SubQ / SCSubcutaneous
An injection into the fatty layer just under the skin.
Common in peptide and metabolic-drug studies. It usually aims for systemic absorption rather than treating only the spot injected.IMIntramuscular
An injection into muscle tissue.
Muscle can absorb a medicine differently from fat. An IM amount should not be assumed to be equivalent to a SubQ amount.IVIntravenous
Delivered directly into a vein.
This gives immediate bloodstream exposure and is commonly used in supervised research or clinical settings. It is not interchangeable with a home injection route.INIntranasal
Delivered through the nose rather than by injection.
The amount delivered depends on formulation and device. A spray count alone does not tell you the dose unless concentration and spray volume are known.Other routes you may see:Oral = swallowed.Topical = applied to skin or another surface.Implant = a formulation placed under the skin by a trained professional.
CALENDAR SETUP
Daily editorial example
Community example · not clinically validatedThe published human dose-response study used a short intravenous infusion. It does not validate this daily subcutaneous pattern or its increases.
Form and route: Injection under the skin, as described in the example
| Calendar stage | Amount each time |
|---|---|
| Weeks 1–2 | 100 mcg |
| Weeks 3–4 | 150 mcg |
| Weeks 5–8 | 200 mcg |
| Weeks 9–12 | 250 mcg |
Frequency: Every day · 1 entry per scheduled day.
This is a finite editorial example. Its ending does not establish a safe course, break or repeat cycle. No repeat is added automatically.
PLAIN-ENGLISH GLOSSARYWhat do the dose terms mean?Open glossary +
mgmilligram
One thousand micrograms (mcg).
mcg / μgmicrogram
One thousandth of a milligram.
mcg/kgweight-based dose
The amount is calculated for each kilogram of body weight.
IUinternational unit
A measure of biological activity used for some medicines; it cannot be converted to mg without compound-specific information.
Routehow it was given
For example SubQ, IM, IV, intranasal, oral or topical.
Frequencyhow often
For example once daily, twice weekly or every seven days.
Titrationplanned step-up or step-down
A protocol changes the amount over time rather than using one fixed amount throughout.
Half-lifehow quickly levels fall
The time taken for the amount of a compound in the body to reduce by roughly half. It can influence study timing but does not by itself define a schedule.
Cyclea defined period of use
Usually means an on-period followed by a stop or review. Many community 'cycles' have not been clinically validated.
Maintenancea continuing phase
A longer-term amount or interval used after an initial phase when a study or authorised treatment actually defines one.
Reconstitutionturning powder into solution
Adding a specified liquid to a freeze-dried vial so a concentration can be calculated.
U-100 unitssyringe volume markings
100 units equals 1 mL on a U-100 insulin syringe. The markings show volume, not peptide mass.
Safety context
SAFETY & UNCERTAINTY
Human evidence shows the hormone signal, not long-term self-use safety
What the current evidence saysThe small acute study does not define longer-term effects on glucose, fluid balance, appetite, IGF-1, sleep or cardiovascular outcomes. Combination use with other GH-axis compounds adds another untested layer.
01 · OBSERVEDPublished safety findings
The summary above reflects the human or preclinical evidence currently represented on this profile.
02 · UNCERTAINGaps still matter
Limited follow-up, small studies or absent controlled trials can leave uncommon and longer-term risks unresolved.
03 · CONTEXTProduct and regulatory status
Route, product identity, quality and regulatory status can materially change the safety context; see the linked status sources below.
Why this matters
Product identity, concentration and sterility matter independently of the peptide theory. Persistent swelling, severe headache, marked glucose symptoms or unusual neurological symptoms need clinical review.
Sources & current status
READ FURTHER
Sources & current status
Follow the professional sources used across this profile, then see how the compound is currently described in regulatory and research terms.
KEY RESEARCH RECORD
2 sourcesSources used on this profile
CURRENT STATUS
How to interpret its position today
No established recovery or body-composition indication
Published human work is a small intravenous pharmacology study, not a validated subcutaneous treatment programme.
Ipamorelin PK/PD study · PubMed ↗Profile reviewed against its linked source record on 20 September 2026. See how evidence is assessed.